Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

NCT03623243 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

185

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Relapsing Multiple Sclerosis
Advancing Multiple Sclerosis

Interventions

DRUG: Siponimod

Sponsor

Novartis Pharmaceuticals